Stifel Nicolaus reissued their buy rating on shares of Cue Biopharma (NASDAQ:CUE - Free Report) in a research report released on Tuesday morning, Benzinga reports. The brokerage currently has a $8.00 price objective on the stock.
Several other equities analysts have also commented on CUE. Oppenheimer reaffirmed an outperform rating and set a $10.00 price target on shares of Cue Biopharma in a research report on Tuesday. Jefferies Financial Group assumed coverage on Cue Biopharma in a report on Wednesday, March 13th. They issued a buy rating and a $6.00 price objective on the stock. Finally, Piper Sandler reiterated an overweight rating and set a $8.00 target price on shares of Cue Biopharma in a report on Wednesday, April 3rd.
Read Our Latest Stock Report on Cue Biopharma
Cue Biopharma Trading Down 6.9 %
Shares of CUE stock traded down $0.14 during mid-day trading on Tuesday, hitting $1.90. 537,918 shares of the company's stock were exchanged, compared to its average volume of 267,397. The stock has a market cap of $92.42 million, a price-to-earnings ratio of -1.60 and a beta of 2.02. The company has a quick ratio of 3.01, a current ratio of 3.01 and a debt-to-equity ratio of 0.11. Cue Biopharma has a fifty-two week low of $1.70 and a fifty-two week high of $5.12. The stock has a 50-day simple moving average of $2.10 and a two-hundred day simple moving average of $2.35.
Institutional Investors Weigh In On Cue Biopharma
A number of large investors have recently modified their holdings of the stock. Swiss National Bank boosted its stake in shares of Cue Biopharma by 8.2% in the first quarter. Swiss National Bank now owns 67,600 shares of the company's stock valued at $330,000 after purchasing an additional 5,100 shares during the period. BlackRock Inc. boosted its position in Cue Biopharma by 4.0% in the 1st quarter. BlackRock Inc. now owns 2,381,267 shares of the company's stock valued at $11,622,000 after buying an additional 90,998 shares during the last quarter. Vanguard Group Inc. boosted its position in Cue Biopharma by 6.6% in the 1st quarter. Vanguard Group Inc. now owns 1,653,737 shares of the company's stock valued at $8,070,000 after buying an additional 102,423 shares during the last quarter. Bridgefront Capital LLC acquired a new stake in shares of Cue Biopharma during the first quarter valued at about $97,000. Finally, XTX Topco Ltd purchased a new stake in shares of Cue Biopharma during the first quarter worth about $172,000. Institutional investors and hedge funds own 35.04% of the company's stock.
About Cue Biopharma
(
Get Free Report)
Cue Biopharma, Inc, a clinical-stage biopharmaceutical company, develops injectable biologics to selectively engage and modulate tumor-specific T cells within the body to treat a range of cancers, chronic infectious diseases, and autoimmune diseases. Its lead drug product candidate is CUE-101, a fusion protein biologic designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers.
Recommended Stories
Before you consider Cue Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cue Biopharma wasn't on the list.
While Cue Biopharma currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
